home / stock / mrns / mrns articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Monday, in an interim analysis of Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) gana...
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 whi...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,11...
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investi...
Monday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced that an independent Data Monitoring Committee (DMC) has recommended continuin...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while...
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASD...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Monday, in an interim analysis of Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) gana...
2024-04-16 08:15:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for MRNS on April 16, 2024 06:31AM ET. The previous analyst recommendation was Overweight. MRNS was trading at $1.3 at issue of the analyst recommendation. The overall analyst consensus : H...